The Paediatric Committee (PDCO) at the European Medicines Agency (EMA), is currently evaluating the development plans for a proposed treatment for achondroplasia. The PDCO would like to reach out to patients or carers living in EUROPE to gather their experiences of living with achondroplasia.

BioMarin announced positive results from the Phase 3 clinical trial for vosoritide (BMN 111) in children with achondroplasia.

Recifercept is the name Pfizer as selected for the orphan drug for achondroplasia. Pfizer acquired Therachon in May 2019, and with that, TA-46, the new molecule being developed as a potential treatment for achondroplasia.

Ascendis Pharma is developing the TransCon CNP program at a swift pace and moving forward with phase 2 ACcomplisH Trial to evaluate the safety and efficacy of TransCon CNP in children with achondroplasia.  

It has been recently published, in August 2019, the "Quality of life of children with achondroplasia and their parents - a German cross-sectional study" at the Orphanet Journal of Rare Diseases. This study investigated the quality of life of children with achondroplasia from children and parent’s perspective and also the parental quality of life.

BioMarin investigational medicine for achondroplasia, BMN-111, known as vosoritide, is currently in phase 3 of the medicine development process and this is an update provided by the company in late July 2019.